Pfizer (PFE) Announces Tofacitinib Phase 3 Met Primary Efficacy Endpoints in Psoriatic Arthritis
Tweet Send to a Friend
Pfizer Inc. (NYSE: PFE) announced top-line results from its first Phase 3 study investigating tofacitinib for the treatment of psoriatic ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
